How to prevent early postmenopausal fracture risk? Proposition of a strategy;Proposition d'une stratégie de prévention du risque fracturaire en début de ménopause

Gynecologie Obstetrique et Fertilite

Volumn 37, Issue 1, 2009, Pages 50-56

  Tremollieres F ^a   Pouilles, J M ^a   Ribot, C ^a  

^a Paul Sabatier University   (France)

Author keywords

Fracture risk; HRT; Postmenopausal osteoporosis; Prevention; Raloxifene; Strategy of treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; RALOXIFENE; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D;

AGE DISTRIBUTION; ARTICLE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ESTROGEN DEFICIENCY; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK POPULATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; RISK REDUCTION; VERTEBRA FRACTURE;

EID: 58349108940     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2008.09.017     Document Type: Article

References (45)

1. Ettinger B., Black D.M., Mitlak B.H., et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized trial. JAMA 282 (1999) 637-645
2. Black D.M., Cummings S.R., Karpf D.B., et al. Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: results of the fracture intervention trial. Lancet 348 (1996) 1535-1541
3. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282 (1999) 1344-1352
4. Chesnut III C.H., Skag A., Christiansen, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
5. Black D.M., Delmas P.D., Eastel R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
6. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
7. Briot K., Trémollieres F., Thomas T., Roux C., and pour le Comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 74 (2007) 24-31
8. Miller P.D., Barlas S., Brenneman S.K., et al. An approach in identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164 (2004) 1113-1120
9. Garnero P., Sornay-Rendu E., Claustrat B., and Delmas P.D. Biochemical markers of bone turnover, endogous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (2002) 1526-1536
10. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., and Delmas P.D. Identification of osteopenic women at high risk of fracture. The OFELY study. J Bone Miner Res 20 (2005) 1813-1819
11. Abrahamsen B., Verstegard P., Rud B., et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish qsteoporosis prevention study. J Bone Miner Res 21 (2006) 796-800
12. Kanis J.A., McCloskey E.V., Johansson H., et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 19 (2008) 1395-1408
13. Traitement médicamenteux de l'ostéoporose post-ménopausique. Afssaps actualisation janvier 2006. http://agmed.sante.gouv.fr.
14. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on the risk of fracture and bone mineral density. The women's health initiative randomized trial. JAMA 290 (2003) 1729-1738
15. Akhter J.P., Lappe J.M., Davies K.M., and Recker R.R. Transmenopausal changes in the trabecular bone structure. Bone 41 (2007) 111-116
16. Wehrli F.W., Ladinsky G.A., Jones C., et al. In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network following menopause and protective effect of estradiol. J Bone Miner Res 23 (2008) 730-740
17. Trémollieres F.A., Pouillès J.M., and Ribot C. Withdrawal of hormone replacement therapy is associated with vertebral bone loss in postmenopausal women. Osteoporos Int 12 (2001) 385-390
18. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., and Cummings S.R. Estrogen replacement therapy and fractures in older women. Ann Intern Med 122 (1995) 9-16
19. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
20. Arnal J.F., Scarabin P.Y., Trémollieres F., Laurell H., and Gourdy P. Estrogens in vascular biology and disease: where do we stand today?. Curr Opin Lipidol 18 (2007) 554-560
21. Scarabin P.Y., Oger E., Plu-Bureau G., and for the ESTHER Study Group. Differential associations of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428
22. Rocca W.A., Grossardt B.R., and Maraganore D.M. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 5 (2008) 257-260
23. MacLennan A.H., Henderson V.W., Paine B.J., et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 13 (2006) 28-36
24. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risk for breast cancer risk associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
25. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
26. ®: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (2004) 1751-1761
27. Vogel V.G., Constantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
28. Greenspan S.L., Brufsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26 (2008) 2644-2652
29. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112 (2008) 1001-1010
30. Bone H.G., Hosking D.H., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
31. ® (CORE) study. J Bone Miner Res 20 (2005) 1514-1524
32. Mellstrom D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75 (2004) 462-468
33. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280 (1998) 2077-2082
34. Delmas P.D., Ensrud K.E., Adachi J.D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
35. Sorensen O.H., Crawford G.M., Mulder H., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
36. Reginster J.Y., Felsenberg D., Boonen S., et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58 (2008) 1687-1695
37. Ensrud K.E., Barrett-Connor E.L., Schwartz A., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension. J Bone Miner Res 19 (2004) 1259-1269
38. Mortensen L., Charles P., Bekker P.J., Digennaro J., and Johnston Jr. C.C. Risedronate increases bone mass is early postmenopausal population: two years of treatement plus one year of follow-up. J Clin Endocrinol Metab 83 (1998) 396-402
39. Neele S.J., Evertz R., De Valk-De Roo G., Roos J.C., and Netelenbos J.C. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30 (2002) 599-603
40. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
41. Mashiba T., Turner C.H., Hirano T., et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
42. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
43. Cheung R.K., Leung K.K., Lee K.C., and Chow T.C. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13 (2007) 485-489
44. Chapurlat R.D., Arlot M., Burt-Pichat B., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 10 (2007) 1502-1509
45. Allen M.R., and Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22 (2007) 1759-1765